
- GCV Symposium keynote interview: “As investors, we need… •
- GCV Symposium panel: Energy and Mobility •
- GCV Symposium fireside chat: Looking beyond the short… •
- GCV Symposium keynote: CVCs as change agents •
- Daily Deal Round Up: May 18, 2022 •
- Corporate venturing grows tepidly in April •
- Britain’s innovation space is stronger than ever despite… •
- Covid-19 drove more corporations to explore venture capital •
- Why do many Venture Capital Funded Start-ups shut… •
- Media sector still in the game after the… •
- Security provides the platform •
- Booming CVC is about to get a reality… •
Flotation/IPO
Daily Deal Round Up: May 6, 2022
The Global Corporate Venturing deal net rounds up the smaller investments from across the corporate innovation ecosystem.
HilleVax racks up $200m in its IPO
The Takeda Vaccines spinoff floated in an upsized offering that granted its former parent $100m in shares.
Daily Deal Round Up: April 27, 2022
Corporate-backed medical imaging technology producer Lunit is preparing to float in South Korea while cancer drug developer Pheast secured $76m from investors including Alexandria Venture Investments.
GemPharmatech gets $175m in initial public offering
The Sinopharm-backed laboratory animal model developer floated on Shanghai Stock Exchange’s Star Market two years after its last equity funding.
Deezer agrees $1.1bn reverse merger
The audio streaming service is set to list with help from a PIPE deal featuring Orange, Access Industries, Warner Music, UMG and Media Participations.
Hinova implements $166m IPO
Tigermed, Fosun, Haisco and Sinopharm-CICC all scored exits as the oncology and metabolic disorder therapeutics went public in China.
HilleVax to attack public markets
The Takeda spinoff is developing a vaccine for acute gastroenteritis caused by norovirus infection, and raised about $140m in August 2021.
Microba makes tracks to ASX
The Macrogen-backed gut microbiome drug developer went public in a $22.5m offering priced at the foot of its range.
Other News
RecBio delivers IPO
The China Resources and Legend Holdings-backed vaccine technology developer floated in Hong Kong in a $97.7m offering following nearly $460m in funding.
Daily Deal Round Up: March 29, 2022
DigitalBridge Ventures led wireless adoption software developer Celona's $60m series C round while Papaya is paying up to $200m for Rakuten-backed payment platform developer Azimo.
GoTo gets $1.1bn in initial public offering
The multicorporate-backed diversified mobile app operator has listed on IDX having priced its shares at near the top of their range.
AN2 Therapeutics prices $69m IPO
The Brii Biosciences-backed lung disease treatment developer priced an upsized offering in the middle of its range.
Hub Cyber Security organises $1.28bn reverse merger
The Axa-backed cybersecurity software provider is set to list through a tie-up with Mount Rainier Acquisition Corp.
Moi moves towards public listing
The KDDI and Sinar Mas-backed video streaming platform developer is scheduled to float on the Tokyo Stock Exchange’s Growth Market on April 27 at a valuation of approximately $51m.
Editor's Picks
Deezer agrees $1.1bn reverse merger
The audio streaming service is set to list with help from a PIPE deal featuring Orange, Access Industries, Warner Music, UMG and Media Participations.
GoTo gets $1.1bn in initial public offering
The multicorporate-backed diversified mobile app operator has listed on IDX having priced its shares at near the top of their range.
GoTo targets $1.1bn in initial public offering
More than 20 corporate backers are due to score exits through an offering that could value the online consumer services portal at nearly $29bn.
Perfect permits billion-dollar reverse merger
The corporate-backed virtual cosmetics app developer’s SPAC merger later this year is set to be boosted by $50m in financing from investors including CyberLink, Chanel, Shiseido and Snap.